Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis. - Saxena A; Yorker M; Zorko NA; Narayan V; Siddiqui BA; Saraiya B; Tester WJ; Mille PJ; Shaver AL; Nikita N; Lu-Yao GL; Kelly WK; et al. (The oncologist, 2026)